Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MED28 (ImmuneEditome ID:80306)

1. Gene summary of enriched editing regions for MED28

Gene summary

Gene information	Gene symbol	MED28
	Gene ID	80306
	GeneSynonyms	1500003D12Rik\|EG1\|magicin
	GeneCytomap	4p15.32
	GeneType	protein-coding
	GeneDescription	mediator of RNA polymerase II transcription subunit 28\|endothelial-derived gene 1\|endothelial-derived protein 1\|mediator of RNA polymerase II transcription, subunit 28 homolog\|merlin and Grb2-interacting cytoskeletal protein\|tumor angiogenesis marker EG-1
	GeneModificationdate	20230329
	UniprotID	Q9H204;H0YAA8
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr4:17626045-17627880:+	ENST00000237380.10	ENSG00000118579.10	MED28	UTR3	AluSx3,AluSc,AluSz,AluYj4,LTR16B1,AluSp,MIRb,MIR	chr4:17626045-17627880:+.alignment
chr4:17628979-17629188:+	ENST00000237380.10	ENSG00000118579.10	MED28	UTR3	AluSx1	chr4:17628979-17629188:+.alignment

Top

2. Tumor-specific enriched editing regions for MED28

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr4:17626045-17627880:+	BRCA	EER	9.2272e-16
ENSG00000118579.10,MED28	BRCA	EAG	1.4108e-14
chr4:17626045-17627880:+	KICH	EER	8.5707e-04
ENSG00000118579.10,MED28	KICH	EAG	7.8573e-04
chr4:17626045-17627880:+	KIRP	EER	1.8997e-02
ENSG00000118579.10,MED28	KIRP	EAG	3.1618e-02
chr4:17626045-17627880:+	LUSC	EER	5.1336e-07
ENSG00000118579.10,MED28	LUSC	EAG	1.1434e-06
chr4:17626045-17627880:+	THCA	EER	4.5533e-07
ENSG00000118579.10,MED28	THCA	EAG	2.6801e-07

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr4:17626045-17627880:+	COAD	Path	EER	4.5330e-02	9.3601e-03	-0.2166
chr4:17626045-17627880:+	KIRC	Path	EER	3.3095e-02	1.2333e-02	0.1229

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for MED28

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr4:17626045-17627880:+

KICH

EER

ENSG00000047662,FAM184B

-0.6871

9.2760e-03

9.4428e-07

-0.5971

CELF2;CNBP;CSTF2T;DDX3X;DGCR8;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;IGF2BP3;NOP56;NOP58;PTBP1;RANGAP1;RBFOX2;RBM6;SRSF1;SRSF7;TAF15;TARDBP;TROVE2;U2AF2;UPF1;YTHDC1

GSVA_HALLMARK_PROTEIN_SECRETION

chr4:17626045-17627880:+

KICH

EER

ENSG00000077063,CTTNBP2

-0.5939

3.0596e-02

5.2841e-06

-0.5624

CNBP;DGCR8;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;LIN28;LIN28B;MOV10;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;RBM10;RC3H1;SRSF1;TAF15;TARDBP;U2AF2;UPF1;YTHDC1;ZC3H7B;ZNF184

Monocytes

GSVA_HALLMARK_PROTEIN_SECRETION

chr4:17626045-17627880:+

KICH

EER

ENSG00000147606,SLC26A7

-0.5879

3.9164e-02

1.7586e-04

-0.4770

CSTF2T;DGCR8;EIF4A3;ELAVL1;EWSR1;FBL;FUS;HNRNPC;HNRNPU;KHSRP;LIN28A;METTL3;NOP56;NOP58;PTBP1;RBFOX2;RBM10;RBM47;SRSF7;TAF15;TARDBP;TROVE2;U2AF2;UPF1;YTHDC1;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_PROTEIN_SECRETION

chr4:17626045-17627880:+

KICH

EER

ENSG00000197712,FAM114A1

-0.5625

4.2150e-02

3.7630e-04

-0.4550

AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PTBP1;RBFOX2;RBM27;RBM47;RBM6;RC3H1;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr4:17626045-17627880:+

KICH

EER

ENSG00000148935,GAS2

-0.5680

4.5422e-02

4.8554e-05

-0.5111

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DGCR8;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;IGF2BP3;ILF3;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NOP56;NOP58;PCBP2;PTBP1;RBFOX2;RBM10;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YWHAG

GAS2

Dendritic_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr4:17626045-17627880:+

KICH

EER

ENSG00000118579,MED28

-0.5469

4.5880e-02

1.5739e-07

-0.6293

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RBM6;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

Dendritic_cells_activated

GSVA_HALLMARK_MYC_TARGETS_V1

chr4:17626045-17627880:+

KICH

EER

ENSG00000149177,PTPRJ

-0.5489

4.6687e-02

6.0424e-05

-0.5055

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RBM6;SAFB2;SBDS;SLBP;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YWHAG;ZC3H7B

PTPRJ

GSVA_HALLMARK_PROTEIN_SECRETION

chr4:17626045-17627880:+

KICH

EER

ENSG00000048028,USP28

-0.5592

4.9071e-02

1.7318e-05

-0.5360

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RBM6;RC3H1;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;ZNF184

USP28

Dendritic_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr4:17626045-17627880:+

ESCA

EER

ENSG00000134996,OSTF1

0.3024

1.5726e-02

7.1216e-09

0.4415

BUD13;CELF2;CNBP;CPSF6;DDX3X;DDX54;DGCR8;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;LARP4B;LIN28;LIN28B;MOV10;NOP56;NOP58;PCBP2;PTBP1;RBFOX2;RBM47;RC3H1;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1;ZNF184

T_cells_CD4_memory_resting

GSVA_HALLMARK_P53_PATHWAY

chr4:17626045-17627880:+

EER

ENSG00000113732,ATP6V0E1

0.3194

1.7122e-05

1.5682e-14

0.4434

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

Macrophages_M1

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results

Top

4. Enriched editing regions and immune related splicing for MED28

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000118579.10,MED28

ESCA

EAG

ENSG00000165275.5

chr9

37773305:37776405:37777600:37778022

-0.4132

6.7290e-04

2.5972e-07

-0.4045

ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RNF219;SF3B4;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MTORC1_SIGNALING

ENSG00000118579.10,MED28

ESCA

EAG

ENSG00000087274.12

chr4

2914883:2915040:2907376:2907844:2907376:2909431

0.3028

1.4147e-02

4.2986e-08

0.4428

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

ENSG00000118579.10,MED28

ESCA

EAG

ENSG00000087274.12

chr4

2907829:2907844:2908514:2909431:2914883:2915040

-0.3028

1.4147e-02

4.2986e-08

-0.4428

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

ENSG00000118579.10,MED28

ESCA

EAG

ENSG00000133704.5

chr12

30628987:30630957:30631122:30631322

-0.1724

3.9719e-02

9.1016e-09

-0.4681

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

B_cells_memory

chr4:17626045-17627880:+

ESCA

EER

ENSG00000087274.12

chr4

2914883:2915040:2907376:2907844:2907376:2909431

0.3046

1.1962e-02

7.4881e-08

0.4370

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

chr4:17626045-17627880:+

ESCA

EER

ENSG00000087274.12

chr4

2907829:2907844:2908514:2909431:2914883:2915040

-0.3046

1.1962e-02

7.4881e-08

-0.4370

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_P53_PATHWAY

chr4:17626045-17627880:+

EER

MEX

ENSG00000010322.11

chr3

52480183:52480295:52480878:52482767:52484529:52484637:52485777:52485827

0.2822

7.8052e-04

7.8608e-12

0.4020

AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

NISCH

T_cells_CD8

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

ENSG00000118579.10,MED28

EAG

ENSG00000123737.8

chr4

121813754:121814047:121816143:121816194

-0.3067

5.4840e-06

1.6033e-10

-0.4248

ACIN1;ADAR;AIFM1;ALYREF;AUH;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM6;RNF219;RTCB;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184

T_cells_CD8

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results

Top

5. Enriched editing regions and immune infiltration for MED28

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr4:17626045-17627880:+	ACC	EER	T_cells_CD4_memory_resting	2.3516e-02	0.5038
ENSG00000118579.10,MED28	ACC	EAG	T_cells_CD4_memory_resting	1.7788e-02	0.5115
chr4:17626045-17627880:+	BLCA	EER	Plasma_cells	1.2145e-02	0.2130
ENSG00000118579.10,MED28	BLCA	EAG	Plasma_cells	2.5451e-02	0.1862
chr4:17626045-17627880:+	BRCA	EER	T_cells_follicular_helper	5.9286e-04	0.1237
ENSG00000118579.10,MED28	BRCA	EAG	Mast_cells_resting	6.2783e-03	-0.0975
chr4:17626045-17627880:+	CESC	EER	T_cells_follicular_helper	3.9158e-03	0.2918
ENSG00000118579.10,MED28	CESC	EAG	B_cells_memory	1.1755e-02	0.2536
chr4:17626045-17627880:+	COAD	EER	NK_cells_activated	4.4548e-02	0.1707
ENSG00000118579.10,MED28	DLBC	EAG	NK_cells_resting	3.4371e-03	0.6216
chr4:17626045-17627880:+	ESCA	EER	T_cells_regulatory_(Tregs)	1.4085e-02	-0.1956
ENSG00000118579.10,MED28	ESCA	EAG	T_cells_regulatory_(Tregs)	4.4509e-03	-0.2252
chr4:17626045-17627880:+	GBM	EER	Macrophages_M0	3.2246e-03	-0.2836
ENSG00000118579.10,MED28	GBM	EAG	Macrophages_M0	4.7657e-03	-0.2637
chr4:17626045-17627880:+	HNSC	EER	T_cells_CD8	2.0073e-02	-0.1916
ENSG00000118579.10,MED28	HNSC	EAG	T_cells_CD8	3.3606e-02	-0.1725
chr4:17626045-17627880:+	KICH	EER	Monocytes	5.7442e-03	0.3614
ENSG00000118579.10,MED28	KICH	EAG	Monocytes	3.3506e-03	0.3790
chr4:17626045-17627880:+	KIRC	EER	Dendritic_cells_resting	4.8642e-02	0.1138
ENSG00000118579.10,MED28	KIRC	EAG	Dendritic_cells_resting	2.7734e-02	0.1256
ENSG00000118579.10,MED28	KIRP	EAG	T_cells_follicular_helper	1.3869e-02	0.2170
chr4:17626045-17627880:+	LAML	EER	Macrophages_M1	4.5571e-02	0.1663
chr4:17626045-17627880:+	LGG	EER	T_cells_CD4_memory_activated	2.3549e-03	0.1378
ENSG00000118579.10,MED28	LGG	EAG	T_cells_CD4_memory_activated	1.3557e-03	0.1448
chr4:17626045-17627880:+	LIHC	EER	T_cells_CD4_memory_activated	6.4317e-03	0.4092
chr4:17626045-17627880:+	LUAD	EER	T_cells_regulatory_(Tregs)	2.2867e-03	0.1781
ENSG00000118579.10,MED28	LUAD	EAG	T_cells_regulatory_(Tregs)	2.7991e-03	0.1703
chr4:17626045-17627880:+	LUSC	EER	Mast_cells_resting	3.2974e-03	-0.1934
ENSG00000118579.10,MED28	LUSC	EAG	Mast_cells_resting	6.4797e-03	-0.1771
chr4:17626045-17627880:+	MESO	EER	T_cells_CD8	1.4789e-02	0.4206
ENSG00000118579.10,MED28	MESO	EAG	T_cells_CD8	1.3087e-02	0.4042
chr4:17626045-17627880:+	OV	EER	Macrophages_M1	1.2883e-02	0.1506
ENSG00000118579.10,MED28	OV	EAG	Macrophages_M1	5.7406e-03	0.1671
chr4:17626045-17627880:+	PAAD	EER	Macrophages_M0	1.2881e-02	0.2688
ENSG00000118579.10,MED28	PAAD	EAG	Macrophages_M0	1.7613e-02	0.2540
chr4:17626045-17627880:+	PCPG	EER	T_cells_regulatory_(Tregs)	3.2455e-03	0.3471
ENSG00000118579.10,MED28	PCPG	EAG	T_cells_regulatory_(Tregs)	1.7471e-02	0.2702
chr4:17626045-17627880:+	PRAD	EER	T_cells_gamma_delta	4.0831e-04	0.1989
ENSG00000118579.10,MED28	PRAD	EAG	T_cells_gamma_delta	2.0739e-04	0.2066
chr4:17626045-17627880:+	SKCM	EER	T_cells_CD8	6.4087e-05	0.2219
ENSG00000118579.10,MED28	SKCM	EAG	T_cells_CD8	3.3004e-04	0.1983
chr4:17626045-17627880:+	STAD	EER	T_cells_CD4_memory_activated	4.5421e-03	0.1545
ENSG00000118579.10,MED28	STAD	EAG	T_cells_CD4_memory_activated	1.8926e-03	0.1686
chr4:17626045-17627880:+	TGCT	EER	Macrophages_M1	2.3176e-02	0.2340
ENSG00000118579.10,MED28	TGCT	EAG	NK_cells_activated	5.1685e-03	0.2832
chr4:17626045-17627880:+	THCA	EER	T_cells_CD4_memory_activated	1.2861e-06	0.2379
ENSG00000118579.10,MED28	THCA	EAG	T_cells_CD4_memory_activated	3.6904e-07	0.2473
chr4:17626045-17627880:+	THYM	EER	T_cells_follicular_helper	9.4145e-04	0.3628
ENSG00000118579.10,MED28	THYM	EAG	T_cells_follicular_helper	1.6589e-03	0.3441
chr4:17626045-17627880:+	UCEC	EER	NK_cells_resting	4.2446e-02	0.2319
ENSG00000118579.10,MED28	UCEC	EAG	NK_cells_resting	1.9621e-02	0.2638
chr4:17626045-17627880:+	UCS	EER	Macrophages_M1	4.9461e-02	-0.3447
ENSG00000118579.10,MED28	UCS	EAG	Macrophages_M1	4.8169e-02	-0.3364
chr4:17626045-17627880:+	UVM	EER	Macrophages_M1	3.3954e-02	0.3242
ENSG00000118579.10,MED28	UVM	EAG	T_cells_CD4_memory_activated	2.8797e-02	0.3336

Top

6. Enriched editing regions and immune gene sets for MED28

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr4:17626045-17627880:+	BRCA	EER	2.5562e-05	0.1513	8.7159e-04	0.1199	2.7800e-02	0.0794	2.4666e-02	0.0811
ENSG00000118579.10,MED28	BRCA	EAG	6.4053e-06	0.1603	1.0311e-03	0.1169	1.6207e-02	0.0858	1.4100e-02	0.0876

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr4:17626045-17627880:+	BLCA	GSVA_HALLMARK_ANGIOGENESIS	EER	2.0922e-05	0.3536
ENSG00000118579.10,MED28	BLCA	GSVA_HALLMARK_ANGIOGENESIS	EAG	4.4305e-05	0.3334
chr4:17626045-17627880:+	BRCA	GSVA_HALLMARK_GLYCOLYSIS	EER	4.9892e-10	0.2220
ENSG00000118579.10,MED28	BRCA	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.2930e-10	0.2268
chr4:17626045-17627880:+	CESC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.9607e-02	-0.2221
ENSG00000118579.10,MED28	CESC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	2.0157e-02	-0.2344
ENSG00000118579.10,MED28	COAD	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.1397e-03	0.2703
chr4:17626045-17627880:+	COAD	GSVA_HALLMARK_GLYCOLYSIS	EER	3.7886e-03	0.2440
ENSG00000118579.10,MED28	DLBC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	4.7594e-02	0.4480
chr4:17626045-17627880:+	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	4.9950e-05	0.3178
ENSG00000118579.10,MED28	ESCA	GSVA_HALLMARK_P53_PATHWAY	EAG	1.4488e-05	0.3375
ENSG00000118579.10,MED28	GBM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	7.4796e-04	-0.3126
chr4:17626045-17627880:+	GBM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.6693e-03	-0.3017
chr4:17626045-17627880:+	HNSC	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	6.6435e-04	0.2776
ENSG00000118579.10,MED28	HNSC	GSVA_HALLMARK_ANGIOGENESIS	EAG	1.0322e-03	0.2636
ENSG00000118579.10,MED28	KICH	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	7.8096e-03	0.3460
chr4:17626045-17627880:+	KICH	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.0162e-02	0.3378
chr4:17626045-17627880:+	KIRC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.2658e-05	0.2487
ENSG00000118579.10,MED28	KIRC	GSVA_HALLMARK_GLYCOLYSIS	EAG	6.3455e-05	0.2262
ENSG00000118579.10,MED28	KIRP	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	1.1775e-03	0.2836
chr4:17626045-17627880:+	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	6.2585e-03	-0.2443
ENSG00000118579.10,MED28	LAML	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	4.0593e-03	0.2373
chr4:17626045-17627880:+	LAML	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	3.2028e-03	0.2432
ENSG00000118579.10,MED28	LGG	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.7025e-07	-0.2305
chr4:17626045-17627880:+	LGG	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	1.6675e-08	0.2527
chr4:17626045-17627880:+	LIHC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.3799e-02	0.3729
ENSG00000118579.10,MED28	LIHC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	4.0045e-03	0.4163
ENSG00000118579.10,MED28	LUAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	8.4550e-04	0.1898
chr4:17626045-17627880:+	LUAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.3633e-02	0.1445
chr4:17626045-17627880:+	LUSC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	3.3277e-03	0.1932
ENSG00000118579.10,MED28	LUSC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	7.0444e-03	0.1754
ENSG00000118579.10,MED28	MESO	GSVA_HALLMARK_P53_PATHWAY	EAG	3.2557e-02	0.3522
chr4:17626045-17627880:+	MESO	GSVA_HALLMARK_DNA_REPAIR	EER	2.8663e-02	0.3811
chr4:17626045-17627880:+	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	9.8144e-09	0.3389
ENSG00000118579.10,MED28	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.3905e-09	0.3519
ENSG00000118579.10,MED28	PAAD	GSVA_HALLMARK_SPERMATOGENESIS	EAG	3.9282e-03	-0.3062
chr4:17626045-17627880:+	PAAD	GSVA_HALLMARK_SPERMATOGENESIS	EER	7.2721e-03	-0.2892
ENSG00000118579.10,MED28	PRAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	4.2830e-04	0.1964
chr4:17626045-17627880:+	PRAD	GSVA_HALLMARK_DNA_REPAIR	EER	4.0739e-04	0.1989
chr4:17626045-17627880:+	READ	GSVA_HALLMARK_P53_PATHWAY	EER	4.5629e-02	0.2869
ENSG00000118579.10,MED28	READ	GSVA_HALLMARK_APOPTOSIS	EAG	2.1160e-02	0.3221
chr4:17626045-17627880:+	SARC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.6000e-03	0.2536
ENSG00000118579.10,MED28	SARC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	2.7502e-03	0.2688
chr4:17626045-17627880:+	SKCM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	6.9807e-05	0.2208
ENSG00000118579.10,MED28	SKCM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	4.3052e-05	0.2252
chr4:17626045-17627880:+	STAD	GSVA_HALLMARK_MTORC1_SIGNALING	EER	3.1698e-03	0.1605
ENSG00000118579.10,MED28	STAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	2.8735e-03	-0.1619
chr4:17626045-17627880:+	TGCT	GSVA_HALLMARK_MYC_TARGETS_V2	EER	4.0147e-03	0.2941
ENSG00000118579.10,MED28	TGCT	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	2.0485e-03	0.3109
ENSG00000118579.10,MED28	THCA	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	3.6691e-06	0.2258
chr4:17626045-17627880:+	THCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	1.0264e-06	0.2400
ENSG00000118579.10,MED28	THYM	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.1405e-06	0.5102
chr4:17626045-17627880:+	THYM	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	9.0524e-07	0.5171
chr4:17626045-17627880:+	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.3448e-03	-0.3418
ENSG00000118579.10,MED28	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	5.9065e-03	-0.3090
chr4:17626045-17627880:+	UCS	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	4.3048e-03	0.4842
ENSG00000118579.10,MED28	UCS	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	3.1729e-03	0.4846
chr4:17626045-17627880:+	UVM	GSVA_HALLMARK_APICAL_SURFACE	EER	6.8834e-03	0.4062
ENSG00000118579.10,MED28	UVM	GSVA_HALLMARK_APICAL_SURFACE	EAG	2.1686e-03	0.4551

Top

7. Enriched editing regions and drugs for MED28

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr4:17626045-17627880:+	ACC	AZD6244	EER	1.0769e-02	0.5568
chr4:17626045-17627880:+	BLCA	Cyclopamine	EER	1.7714e-04	-0.3139
ENSG00000118579.10,MED28	BLCA	Cyclopamine	EAG	4.6853e-04	-0.2878
chr4:17626045-17627880:+	BRCA	CCT007093	EER	2.1749e-07	0.1857
ENSG00000118579.10,MED28	BRCA	CCT007093	EAG	1.7474e-07	0.1852
chr4:17626045-17627880:+	CESC	Erlotinib	EER	2.5463e-02	-0.2280
ENSG00000118579.10,MED28	CESC	Erlotinib	EAG	9.5535e-03	-0.2606
ENSG00000118579.10,MED28	COAD	Midostaurin	EAG	9.3288e-04	0.2748
chr4:17626045-17627880:+	COAD	BIRB.0796	EER	3.0817e-03	0.2493
ENSG00000118579.10,MED28	DLBC	JW.7.52.1	EAG	3.4824e-03	-0.6209
chr4:17626045-17627880:+	ESCA	BI.D1870	EER	1.0213e-02	-0.2045
ENSG00000118579.10,MED28	ESCA	BI.D1870	EAG	8.1458e-03	-0.2098
ENSG00000118579.10,MED28	GBM	BAY.61.3606	EAG	9.4128e-06	0.4034
chr4:17626045-17627880:+	GBM	BAY.61.3606	EER	7.3427e-05	0.3754
chr4:17626045-17627880:+	HNSC	AZD.0530	EER	4.1414e-04	-0.2875
ENSG00000118579.10,MED28	HNSC	AZD.0530	EAG	5.8472e-04	-0.2758
ENSG00000118579.10,MED28	KICH	Erlotinib	EAG	8.9124e-05	-0.4916
chr4:17626045-17627880:+	KICH	Erlotinib	EER	1.7163e-04	-0.4777
chr4:17626045-17627880:+	KIRC	GNF.2	EER	1.3678e-06	-0.2742
ENSG00000118579.10,MED28	KIRC	MG.132	EAG	1.0660e-06	-0.2747
ENSG00000118579.10,MED28	KIRP	AZD6482	EAG	1.3397e-09	0.5038
chr4:17626045-17627880:+	KIRP	AZD6482	EER	1.2391e-06	0.4195
ENSG00000118579.10,MED28	LAML	AG.014699	EAG	6.9892e-03	0.2231
chr4:17626045-17627880:+	LAML	AG.014699	EER	9.0775e-03	0.2160
ENSG00000118579.10,MED28	LGG	MG.132	EAG	3.6802e-07	-0.2280
chr4:17626045-17627880:+	LGG	MG.132	EER	5.7496e-09	-0.2605
chr4:17626045-17627880:+	LIHC	Bortezomib	EER	3.0550e-02	-0.3303
ENSG00000118579.10,MED28	LIHC	Bortezomib	EAG	2.3038e-02	-0.3346
ENSG00000118579.10,MED28	LUAD	Dasatinib	EAG	2.1610e-04	-0.2100
chr4:17626045-17627880:+	LUAD	Dasatinib	EER	1.7390e-03	-0.1828
chr4:17626045-17627880:+	LUSC	AP.24534	EER	4.7819e-03	0.1858
ENSG00000118579.10,MED28	LUSC	Bortezomib	EAG	6.9733e-03	-0.1756
ENSG00000118579.10,MED28	MESO	LFM.A13	EAG	8.2167e-03	-0.4281
chr4:17626045-17627880:+	MESO	KIN001.135	EER	8.5476e-03	-0.4503
chr4:17626045-17627880:+	OV	Bexarotene	EER	5.1731e-09	0.3449
ENSG00000118579.10,MED28	OV	Bexarotene	EAG	8.4221e-09	0.3403
ENSG00000118579.10,MED28	PAAD	BX.795	EAG	1.8458e-02	0.2522
chr4:17626045-17627880:+	PAAD	AZD6482	EER	2.1741e-02	0.2532
chr4:17626045-17627880:+	PCPG	LFM.A13	EER	1.7724e-02	-0.2827
ENSG00000118579.10,MED28	PCPG	CCT007093	EAG	4.2770e-02	-0.2315
ENSG00000118579.10,MED28	PRAD	BMS.509744	EAG	3.1892e-04	-0.2006
chr4:17626045-17627880:+	PRAD	BMS.536924	EER	6.0285e-05	-0.2255
chr4:17626045-17627880:+	SARC	BMS.536924	EER	1.3757e-03	-0.2912
ENSG00000118579.10,MED28	SARC	AG.014699	EAG	7.3212e-04	0.3017
ENSG00000118579.10,MED28	SKCM	CGP.082996	EAG	1.2542e-04	-0.2115
chr4:17626045-17627880:+	SKCM	BIBW2992	EER	1.1858e-07	-0.2912
chr4:17626045-17627880:+	STAD	CCT007093	EER	3.6197e-03	0.1583
ENSG00000118579.10,MED28	STAD	CCT007093	EAG	3.0801e-03	0.1608
chr4:17626045-17627880:+	TGCT	AS601245	EER	8.0200e-03	0.2719
ENSG00000118579.10,MED28	TGCT	Cyclopamine	EAG	1.1986e-02	-0.2555
ENSG00000118579.10,MED28	THCA	Embelin	EAG	1.2202e-10	0.3102
chr4:17626045-17627880:+	THCA	Embelin	EER	1.4502e-12	0.3422
ENSG00000118579.10,MED28	THYM	Metformin	EAG	5.7214e-06	-0.4802
chr4:17626045-17627880:+	THYM	AKT.inhibitor.VIII	EER	6.9043e-06	0.4792
ENSG00000118579.10,MED28	UCEC	GNF.2	EAG	1.2348e-03	-0.3593
chr4:17626045-17627880:+	UCEC	A.770041	EER	6.3835e-04	-0.3806
chr4:17626045-17627880:+	UCS	CCT007093	EER	2.5638e-04	0.5955
ENSG00000118579.10,MED28	UCS	GDC.0449	EAG	3.0996e-04	-0.5742
chr4:17626045-17627880:+	UVM	Dasatinib	EER	1.0174e-02	-0.3879
ENSG00000118579.10,MED28	UVM	GSK269962A	EAG	9.7133e-03	-0.3901

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType